ORKA — Oruka Therapeutics Share Price
Last trade - 00:00- $400.99m
- $28.27m
- 42
- 34
- 36
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.06 | ||
| Price to Tang. Book | 1.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.01% | ||
| Return on Equity | -40.22% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Directors
- Robert Conway NEC (67)
- Michael Bristow CEO (76)
- C. Jeffrey Dekker CFO (56)
- Thomas Keuer COO (62)
- Christopher Ozeroff SVP (62)
- Christopher Graybill VPR
- Linda Grais IND (64)
- Anders Hove IND (55)
- Daniel Mitchell IND (64)
- Raymond Woosley IND (78)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 16th, 2004
- Public Since
- July 21st, 2000
- No. of Shareholders
- 20
- No. of Employees
- 28
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 37,440,510
- Address
- 855 Oak Grove Ave., Suite 100, MENLO PARK, 94025
- Web
- https://orukatx.com/
- Phone
- +1 6506067910
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for ORKA
Similar to ORKA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
As of Today at 22:30 UTC, shares in Oruka Therapeutics are trading at $10.71. This share price information is delayed by 15 minutes.
Shares in Oruka Therapeutics last closed at $10.71 and the price had moved by -49.1% over the past 365 days. In terms of relative price strength the Oruka Therapeutics share price has underperformed the S&P500 Index by -54.1% over the past year.
The overall consensus recommendation for Oruka Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOruka Therapeutics does not currently pay a dividend.
Oruka Therapeutics does not currently pay a dividend.
Oruka Therapeutics does not currently pay a dividend.
To buy shares in Oruka Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $10.71, shares in Oruka Therapeutics had a market capitalisation of $400.99m.
Here are the trading details for Oruka Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ORKA
Based on an overall assessment of its quality, value and momentum Oruka Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Oruka Therapeutics is $39.86. That is 272.18% above the last closing price of $10.71.
Analysts covering Oruka Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.40 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oruka Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -60.43%.
As of the last closing price of $10.71, shares in Oruka Therapeutics were trading -42.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oruka Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.71.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Oruka Therapeutics' management team is headed by:
- Robert Conway - NEC
- Michael Bristow - CEO
- C. Jeffrey Dekker - CFO
- Thomas Keuer - COO
- Christopher Ozeroff - SVP
- Christopher Graybill - VPR
- Linda Grais - IND
- Anders Hove - IND
- Daniel Mitchell - IND
- Raymond Woosley - IND